FOLFOXIRI + Bevacizumab

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-IRINOTECAN` `DRUG-OXALIPLATIN` `DRUG-LEUCOVORIN` `DRUG-5-FLUOROURACIL` `DRUG-BEVACIZUMAB`

ID	`REG-FOLFOXIRI-BEV`
Type	Regimen
Status	reviewed 2026-05-03 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-COLON-2024` `SRC-NCCN-COLON-2025` `SRC-TRIBE-LOUPAKIS-2014` `SRC-TRIBE2-CREMOLINI-2020`

Notes

Triplet backbone (irinotecan + oxaliplatin + 5-FU/LV) + bevacizumab. TRIBE: mOS 29.8 vs 25.8 mo vs FOLFIRI+bev (HR 0.80). TRIBE2: PFS2 19.2 vs 16.4 mo (HR 0.74). Substantially more toxic than doublet; requires ECOG 0-1, age ideally <75, normal organ function, no prior pelvic radiation to bowel. G-CSF prophylaxis mandatory. Preferred for: high tumour burden, conversion-intent liver-limited disease, BRAF V600E mCRC (poor prognosis, benefit from aggressive induction). Not appropriate for frail, elderly, or post-bowel resection patients with impaired recovery.

Used By

Handbook Chapters

HB-CRC-METASTATIC-1L - Metastatic colorectal cancer: first-line biomarker reasoning

Indication

IND-CRC-METASTATIC-1L-FOLFOXIRI-BEV - IND-CRC-METASTATIC-1L-FOLFOXIRI-BEV